Pediatric Cancer Research Foundation

Eliminate Childhood Cancer Through Leading-Edge Research

aka NVRQT   |   Irvine, CA   |  https://pcrf-kids.org/

Mission

The Pediatric Cancer Research Foundation identifies and invests in leading edge research that demonstrates the best hope for a cure to childhood cancer. Founded in 1982 by physicians, parents and community leaders, Pediatric Cancer Research Foundation (PCRF) has raised over $48 Million for cancer research since its inception. This represents the persistent hard work of physicians, researchers, volunteers, staff and community partners who are dedicated to the health of our future generation—our children.

Ruling year info

1983

Principal Officer

Ms Jeri B Wilson

Main address

17932 Sky Park Circle, Suite E

Irvine, CA 92614 USA

Show more contact info

EIN

95-3772528

NTEE code info

Pediatrics Research (H98)

Cancer (G30)

IRS filing requirement

This organization is required to file an IRS Form 990 or 990-EZ.

Sign in or create an account to view Form(s) 990 for 2020, 2019 and 2018.
Register now

Communication

Programs and results

What we aim to solve

SOURCE: Self-reported by organization

The Pediatric Cancer Research Foundation identifies and invests in leading edge research that demonstrates the best hope for a cure to childhood cancer

Our programs

SOURCE: Self-reported by organization

What are the organization's current programs, how do they measure success, and who do the programs serve?

Translational Grant Program at Dana Farber Cancer Institute

Program Title: Bridging the gap between target discovery and clinical trials in pediatric Ewing sarcoma Ewing sarcoma is the second most common bone cancer in children. Although cure rates in children with localized disease approach 75%, current treatment combines intensive chemotherapy, surgery, and radiation for which there is an alarming rate of long-term side effects. Furthermore, for patients with disseminated or recurrent disease, current treatment regimens are largely ineffective. Therefore, there is a great need for new and innovative treatments for patients diagnosed with Ewing sarcoma. In recent work, Dr. Crompton has shown that Ewing sarcoma tumor cells express a highly active protein, focal adhesion kinase (FAK). Inhibition of FAK results in cancer cell death and slows tumor growth in multiple experimental models of Ewing sarcoma. This suggests that FAK inhibition may be a new, targeted approach for treating patients with this disease. With several FAK inhibitors in early-phase clinical trials for adult cancers, this approach could be translatable to patients with Ewing sarcoma in the near future.

Population(s) Served
Infants and toddlers

The Pediatric Cancer Translational Research Program focuses on four areas of research: 1) Stem cell transplantation and gene therapy for leukemia and lymphoma – Drs. Satiro de Oliveira/Ted Moore/Don Kohn/Gay Crooks, 2) The Pediatric Sarcoma Translational Research Program: Spanning the gap from bench to bedside – Dr. Noah Federman, 3) Dendritic Cell Vaccination for Pediatric High-Grade Glioma Patients – Dr. Tom Davidson, 4) Next generation sequencing and pediatric cancer predisposition – Dr. Vivian Chang. Members of the Pediatric Hematology/Oncology Division are members of COG, PBMTC, SARC, PPNOC, NYMC consortium among others.

Population(s) Served
Adolescents

Program Title: Targeted Inhibition of CREB for the Treatment of Pediatric Acute Leukemias The overall survival of pediatric patients with acute myeloid leukemia (AML) is 50% and less than 30% with relapsed acute lymphoblastic leukemia (ALL). CREB (cAMP Response Element Binding Protein) is a protein that is overproduced in leukemia cells from patients in AML. CREB increases the growth and survival of immature blood cells resulting in AML. In addition, overexpression of the CREB protein in AML patients was associated with an increased risk of relapse and decrease in survival. Knocking down CREB in AML cells resulted in cell death but had no long-term effects on normal blood stem cells. Therefore, we propose that CREB and its downsteam pathways may provide an alternative approach to treat acute leukemia. We developed a small molecule compound that blocks the interaction of CREB and its binding partner CBP (CREB Binding Protein). Our hope is that CREB inhibitors will lead to discovery of a new class of drugs that will be used to treat acute leukemia.   The quick brown fox jumps over the lazy dog.

Population(s) Served
Infants and toddlers

Program title: Development of Tunable ON-OFF CAR T Cells for Safe and Durable Tumor Control Clinical trials conducted by our Ben Towne Center for Childhood Cancer Research (BTCCCR) at the Seattle Children's Hospital have reported 94% remission rates in patients with relapsed or refractory leukemia using T cells engineered to recognize and "kill" tumor cells based on specific cell surface proteins. Referred to as chimeric antigen receptor (CAR) T cell therapy, this strategy is also being tested against solid tumors (such as brain tumors and neuroblastoma) in ongoing FDA-approved clinical trials at the Seattle Children's Hospital. However, solid tumors pose formidable challenges to CAR T cell therapy - of note is the loss of T cell function inside solid tumors. It is believed that with repetitive attacks against tumors, T cells slowly enter a state of "exhaustion" or dysfunction wherein they shutdown their anti-tumor functions. This state of inaction is reinforced through negative signals from tumor cells, which further suppress their metabolic capacity for mounting an anti-tumor attack.

Population(s) Served
Adolescents

The PCRF Laboratory Research Program at MFCH at NYMC is focused on fiveoverarching areas of research/hypotheses. These state of the art research initiatives include: 1) cancer genetics and treatment of childhood and adolescent hematological malignancies; 2) genetically re-engineering immune cells to enhance targeted adoptive cellular cancer immunotherapy; 3) tumor immunology and identifying targets for humoral targeted immunotherapy; 4) stem cell biology, cancer stem cells, and regenerative therapy; and 5) translational therapeutic consortiums for childhood and adolescent cancer therapy.

Population(s) Served
Adults

Where we work

Accreditations

Better Business Bureau Wise Giving Alliance 2018

Charity Navigator 2018

Charity Navigator 2019

Charity Navigator 2020

Our results

SOURCE: Self-reported by organization

How does this organization measure their results? It's a hard question but an important one.

Total dollar amount of grants awarded

This metric is no longer tracked.
Totals By Year
Population(s) Served

Children and youth, People with diseases and illnesses

Type of Metric

Output - describing our activities and reach

Direction of Success

Increasing

Context Notes

Pediatric Cancer Research Foundation is dedicated to awarding the maximum amount of research funding as possible.

Cumulative number of leading institutions funded

This metric is no longer tracked.
Totals By Year
Population(s) Served

Young adults, Children and youth, Chronically ill people, Terminally ill people

Type of Metric

Output - describing our activities and reach

Direction of Success

Increasing

Context Notes

Pediatric Cancer Research Foundation believes in supporting research from the emerging grant stage through basic science. It is from these relationships that innovative advancement can be made.

Total number of grants awarded

This metric is no longer tracked.
Totals By Year
Population(s) Served

Children and youth, People with diseases and illnesses

Type of Metric

Output - describing our activities and reach

Direction of Success

Increasing

Context Notes

Thanks to your support, PCRF is able to extend support to multiple researchers annually. This metric represents the cumulative number of grants.

Number of principal investigators funded

This metric is no longer tracked.
Totals By Year
Population(s) Served

Children and youth, People with diseases and illnesses

Type of Metric

Output - describing our activities and reach

Direction of Success

Increasing

Context Notes

Pediatric Cancer Research Foundation is proud to be fighting cancer coast to coast. As we expand our footprint we make strides toward a cure. Please see our website for a detailed grant history.

Number of PCRF Survivor Schoarships funded

This metric is no longer tracked.
Totals By Year
Population(s) Served

Adults, People with diseases and illnesses

Type of Metric

Output - describing our activities and reach

Direction of Success

Increasing

Context Notes

Pediatric Cancer Research Foundation Survivor Scholarship Fund (established in 2017) is a fulfillment of the commitment to a quality of life for survivors. We fund as many scholarships as possible.

Our Sustainable Development Goals

SOURCE: Self-reported by organization

Learn more about Sustainable Development Goals.

Goals & Strategy

SOURCE: Self-reported by organization

Learn about the organization's key goals, strategies, capabilities, and progress.

Charting impact

Four powerful questions that require reflection about what really matters - results.

Our goal is to identify and fund leading researchers in support of finding less toxic treatments for children battling cancer. At PCRF we are dedicated to giving families hope for a healthy future.

PCRF has made substantial strides and growth in the corporate world of employee giving and matching gifts. Many companies have found us and support the work we do through our high rating on national Charity websites. We believe that keeping a high level of financial transparency while keeping our costs down truly shows the donor community that we will invest their money in key research quickly and effectively.

Our grant cycle is open from January 1-March 1 every year and open for submission for every level of research. Emerging researchers to seasoned advanced research teams.

With and external confidential review panel of their peers and our own internal review panel, we work do find grants in all areas of pediatric cancer research for funding.

PCRF currently has a passionate senior-level staff and C suite level board members driving public awareness and fundraising for our grants. Keeping our costs down while focusing on key successful fundraising platforms, PCRF has attracted new donors, corporations, foundations from across the country all joining forces to find a cure. Legacy board adds historical strength as we move into new platforms to align with multiple generations of giving.

PCRF started as a grass-roots organization based out of Orange County, California. Today, PCRF funds researchers across the nation in the following hospitals, research centers, and universities: New York Medical College (Valhalla, NY), Seattle Children's Hospital (Seattle, WA), UCSF (San Francisco, CA), Dana-Farber Cancer Institute (Boston, MA), City of Hope (Duarte, CA) UCLA Mattel Children's Hospital (Los Angeles, CA), MD Anderson Cancer Center (Houston, TX), Beckman Research Institute of City of Hope (Los Angeles, CA), Stanford University (Palo Alto, CA), Baylor College of Medicine (Houston, TX), Texas Children's Hospital (Houston, TX)Case Western University School of Medicine (Columbus, OH), Children's Hospital of Philadelphia (Philadelphia, PA), Ann and Robert Lurie Children's Hospital (IL).

Financials

Pediatric Cancer Research Foundation
lock

Unlock financial insights by subscribing to our monthly plan.

Subscribe

Unlock nonprofit financial insights that will help you make more informed decisions. Try our monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights?
Learn more about GuideStar Pro.

Operations

The people, governance practices, and partners that make the organization tick.

lock

Connect with nonprofit leaders

Subscribe

Build relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.

lock

Connect with nonprofit leaders

Subscribe

Build relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.

Pediatric Cancer Research Foundation

Board of directors
as of 12/17/2021
SOURCE: Self-reported by organization
Board co-chair

Steve Giusto

Philanthropist

Term: 2019 - 2021


Board co-chair

John Weiner

CBRE

Term: 2019 - 2021

Keith Koeller

Koeller, Nebeker, Carlson & Haluck LLP

Troy Varenchik

Deloitte LLP

John Weiner

CB Richard Ellis

Tim Cromwell

RD Olson Construction

Scott Ecker

Deloitte LLP

Elizabeth McNulty

Evans Fears & Schuttert LLP

John Vallely

Community Volunteer

Susie Buchan

Community Volunteer

Daniel Mitchell

Wescorp Builders

Janet Mitchell

Community Volunteer

Brad Neglia

LBA Realty

Cherie Daly

Celularity, Inc.

Thomas Brennan

Prudential

Cameron Munson

Orange Aluminum

John Coon

Private Wealth Management

Beth Abrams

Philanthropist

Len Shulman

Shulman Bastian Friedman and Bui LLP

Board leadership practices

SOURCE: Self-reported by organization

GuideStar worked with BoardSource, the national leader in nonprofit board leadership and governance, to create this section.

  • Board orientation and education
    Does the board conduct a formal orientation for new board members and require all board members to sign a written agreement regarding their roles, responsibilities, and expectations? Yes
  • CEO oversight
    Has the board conducted a formal, written assessment of the chief executive within the past year ? Yes
  • Ethics and transparency
    Have the board and senior staff reviewed the conflict-of-interest policy and completed and signed disclosure statements in the past year? Yes
  • Board composition
    Does the board ensure an inclusive board member recruitment process that results in diversity of thought and leadership? Not applicable
  • Board performance
    Has the board conducted a formal, written self-assessment of its performance within the past three years? Yes

Organizational demographics

SOURCE: Self-reported; last updated 6/24/2021

Who works and leads organizations that serve our diverse communities? GuideStar partnered on this section with CHANGE Philanthropy and Equity in the Center.

Leadership

The organization's leader identifies as:

Gender identity
Female

Race & ethnicity

No data

Gender identity

 

Sexual orientation

No data

Disability

No data

Equity strategies

Last updated: 11/04/2019

GuideStar partnered with Equity in the Center - an organization that works to shift mindsets, practices, and systems to increase racial equity - to create this section. Learn more

Data
  • We have long-term strategic plans and measurable goals for creating a culture such that one’s race identity has no influence on how they fare within the organization.
Policies and processes
  • We use a vetting process to identify vendors and partners that share our commitment to race equity.
  • We have a promotion process that anticipates and mitigates implicit and explicit biases about people of color serving in leadership positions.
  • We seek individuals from various race backgrounds for board and executive director/CEO positions within our organization.
  • We have community representation at the board level, either on the board itself or through a community advisory board.
  • We help senior leadership understand how to be inclusive leaders with learning approaches that emphasize reflection, iteration, and adaptability.